Ignite Creation Date:
2025-12-24 @ 10:51 PM
Ignite Modification Date:
2026-02-22 @ 2:04 AM
Study NCT ID:
NCT02419469
Status:
TERMINATED
Last Update Posted:
2018-06-11
First Post:
2015-04-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D054198', 'term': 'Precursor Cell Lymphoblastic Leukemia-Lymphoma'}, {'id': 'D008223', 'term': 'Lymphoma'}], 'ancestors': [{'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007945', 'term': 'Leukemia, Lymphoid'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003561', 'term': 'Cytarabine'}, {'id': 'D003630', 'term': 'Daunorubicin'}, {'id': 'D014750', 'term': 'Vincristine'}, {'id': 'D011241', 'term': 'Prednisone'}, {'id': 'C042705', 'term': 'pegaspargase'}, {'id': 'C527517', 'term': 'ofatumumab'}, {'id': 'D000069283', 'term': 'Rituximab'}, {'id': 'D008727', 'term': 'Methotrexate'}, {'id': 'D003520', 'term': 'Cyclophosphamide'}, {'id': 'D015122', 'term': 'Mercaptopurine'}, {'id': 'D004317', 'term': 'Doxorubicin'}, {'id': 'C018038', 'term': 'dexamethasone acetate'}, {'id': 'D002123', 'term': 'Calcium Dobesilate'}, {'id': 'D013866', 'term': 'Thioguanine'}], 'ancestors': [{'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D001087', 'term': 'Arabinonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D018943', 'term': 'Anthracyclines'}, {'id': 'D009279', 'term': 'Naphthacenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D000617', 'term': 'Aminoglycosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D014748', 'term': 'Vinca Alkaloids'}, {'id': 'D046948', 'term': 'Secologanin Tryptamine Alkaloids'}, {'id': 'D026121', 'term': 'Indole Alkaloids'}, {'id': 'D000470', 'term': 'Alkaloids'}, {'id': 'D007211', 'term': 'Indoles'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D054836', 'term': 'Indolizidines'}, {'id': 'D007212', 'term': 'Indolizines'}, {'id': 'D011244', 'term': 'Pregnadienediols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D058846', 'term': 'Antibodies, Monoclonal, Murine-Derived'}, {'id': 'D000911', 'term': 'Antibodies, Monoclonal'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D000630', 'term': 'Aminopterin'}, {'id': 'D011622', 'term': 'Pterins'}, {'id': 'D011621', 'term': 'Pteridines'}, {'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D013438', 'term': 'Sulfhydryl Compounds'}, {'id': 'D013457', 'term': 'Sulfur Compounds'}, {'id': 'D011687', 'term': 'Purines'}, {'id': 'D001557', 'term': 'Benzenesulfonates'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D001190', 'term': 'Arylsulfonates'}, {'id': 'D017739', 'term': 'Arylsulfonic Acids'}, {'id': 'D013451', 'term': 'Sulfonic Acids'}, {'id': 'D013456', 'term': 'Sulfur Acids'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'CR_Study_Registration@mdanderson.org', 'phone': '713-792-7734', 'title': 'Rytting,Michael E.,M.D. / PEDIATRICS', 'organization': 'UT MD Anderson Cancer Center'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': '4 weeks', 'eventGroups': [{'id': 'EG000', 'title': 'Ofatumumab Plus Chemotherapy', 'description': 'Ofatumumab plus chemotherapy. Only one patient enrolled prior to termination.', 'otherNumAtRisk': 1, 'deathsNumAtRisk': 1, 'otherNumAffected': 0, 'seriousNumAtRisk': 1, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Event Free Survival (EFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Ofatumumab Plus Chemotherapy', 'description': 'Ofatumumab plus chemotherapy. Only one patient enrolled prior to termination.'}], 'classes': [{'categories': [{'measurements': [{'value': 'NA', 'comment': 'Participant was lost to follow up.', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '3 years', 'description': 'Event free survival defined as the time from treatment to relapse of leukemia or death for any reason or lost to follow-up. Study regimen considered successful if it exhibits a 3-year EFS rate greater than 65% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Ofatumumab Plus Chemotherapy', 'description': 'Ofatumumab plus chemotherapy. Only one patient enrolled prior to termination.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Ofatumumab Plus Chemotherapy', 'description': 'Ofatumumab plus chemotherapy. Only one patient enrolled prior to termination.'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2015-03-12', 'size': 768193, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2018-05-03T11:26', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 1}}, 'statusModule': {'whyStopped': 'Slow Accrual', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2015-11-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-05', 'completionDateStruct': {'date': '2017-06-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-05-09', 'studyFirstSubmitDate': '2015-04-14', 'resultsFirstSubmitDate': '2018-05-09', 'studyFirstSubmitQcDate': '2015-04-16', 'lastUpdatePostDateStruct': {'date': '2018-06-11', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-05-09', 'studyFirstPostDateStruct': {'date': '2015-04-17', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-06-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-06-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Event Free Survival (EFS)', 'timeFrame': '3 years', 'description': 'Event free survival defined as the time from treatment to relapse of leukemia or death for any reason or lost to follow-up. Study regimen considered successful if it exhibits a 3-year EFS rate greater than 65% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Leukemia', 'Precursor-B acute lymphoblastic leukemia', 'ALL', 'Lymphoblastic lymphoma', 'LL', 'Lymphoma', 'Cytarabine', 'Ara-C', 'Cytosar', 'DepoCyt', 'Cytosine Arabinosine Hydrochloride', 'Daunorubicin', 'Daunorubicin Hydrochloride', 'Cerubidine', 'Daunomycin', 'DNR', 'Vincristine', 'Prednisone', 'PEG asparaginase', 'Pegaspargase', 'Oncaspar', 'Polyethylene glycol conjugated lasparaginase-H', 'Ofatumumab', 'Arzerra', 'Rituximab', 'Rituxan', 'Methotrexate', 'Cyclophosphamide', 'Cytoxan', 'Neosar', 'Mercaptopurine', '6-mercaptopurine', 'Purinethol', '6-MP', 'Doxorubicin', 'Doxorubicin hydrochloride', 'Adriamycin PFS', 'Adriamycin RDF', 'Adriamycin', 'Rubex', 'Dexamethasone', 'Decadron', 'Thioguanine', '6-thioguanine'], 'conditions': ['Leukemia', 'Precursor-B Acute Lymphoblastic Leukemia', 'Lymphoblastic Lymphoma', 'Lymphoma']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://www.mdanderson.org', 'label': 'University of Texas MD Anderson Cancer Center Website'}]}, 'descriptionModule': {'briefSummary': 'The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in patients who are 12-30 years of age. The safety of these drug combinations will also be studied.\n\nAugmented BFM is made up of daunorubicin, vincristine, prednisone, dexamethasone, PEG asparaginase, and methotrexate.', 'detailedDescription': "Study Drug Administration:\n\nIf you are found to be eligible to take part in this study, on Day 1 or during the spinal tap procedure, you will be given cytarabine as an injection in your spinal fluid.\n\nYou will then receive the study drugs in Induction, Consolidation, and Maintenance Courses. Induction Therapy is designed to remove the signs of leukemia that can be seen and to allow normal blood cells to be restored. This is called remission. Consolidation and Maintenance Therapies are designed to cause the disease to stay in remission.\n\nThe study drugs will be given the following ways:\n\n* Daunorubicin by vein over about 30 minutes\n* Vincristine by vein over 15-30 minutes\n* PEG asparaginase by vein over 15-60 minutes\n* Methotrexate either by mouth or as an injection into your spinal fluid (intrathecal), depending on the course. When given through the spinal fluid, cerebrospinal fluid (CSF) will be collected with each spinal tap to test the fluid for leukemia. If there is disease in your spinal fluid before starting the treatment, you will be given additional methotrexate doses each week until there is no disease present.\n* Ofatumumab as an injection or by vein. If given by vein, the length of the infusion will depend on how well you tolerate the drug. If ofatumumab is not available, you will be given rituximab by vein over several (about 4-6) hours.\n* Cyclophosphamide by vein over about 1 hour\n* Cytarabine as an injection under the skin or by vein. If given by vein, the length of the infusion will depend on how well you tolerate the drug.\n* Doxorubicin by vein. If given by vein, the length of the infusion will depend on how well you tolerate the drug.\n* Prednisone, 6-Mercaptopurine, dexamethasone, and 6-Thioguanine are all taken by mouth\n\nWithin 3 days after you receive cytarabine, you will begin the Induction Course, which will last for 4 weeks. In the Induction Course, you will receive:\n\n* Daunorubicin and vincristine on Days 1, 8, 15, and 22\n* PEG asparaginase 1 time during Week 1\n* Prednisone each day on Days 1-28.\n* Intrathecal methotrexate at Weeks 2 and 5 during a spinal tap. If the is disease in your spinal fluid before starting the treatment, you will be given additional methotrexate doses each week until there is no disease present.\n* Ofatumumab or rituximab on Days 2 and 15\n\nDepending on how you respond to Induction, you may begin the Consolidation Courses 1-4 weeks after Induction.\n\nYou will then receive Consolidation Course 1. This course will last 8 weeks, and you will receive:\n\n* Cyclophosphamide at Weeks 1 and 5\n* Cytarabine on or around Days 1-4 and Days 8-11 of each 4-week cycle\n* 6-Mercaptopurine on Days 1-14 of each 4-week cycle\n* Vincristine at Weeks 3 and 4 of each 4-week cycle\n* PEG Asparaginase at Weeks 3 and 7\n* Intrathecal methotrexate weekly during Month 1 only\n* Ofatumumab or rituximab at Weeks 1 and 5\n\nYou will then receive 2 courses of Consolidation Course 2. Each course will last about 7 weeks, and you will receive:\n\n* Vincristine and methotrexate every 10 (+/- 2) days for up to 5 doses\n* PEG Asparaginase at Weeks 1 and 4\n* Intrathecal methotrexate at Weeks 1 and 5\n* Ofatumumab or rituximab at Weeks 1 and 5\n\nYou will then receive Consolidation 3 (Part A). This course will last for 4 weeks, and you will receive:\n\n* Vincristine and doxorubicin at Weeks 1, 2, and 3\n* Dexamethasone on Days 1-7 and Days 15-21\n* PEG asparaginase at Week 1\n* Intrathecal methotrexate at Week 1\n* Ofatumumab or rituximab on Weeks 1 and 3\n\nYou will then receive Consolidation 3 (Part B). This course will last for 4 weeks, and you will receive:\n\n* Cyclophosphamide at Week 1\n* Cytarabine for 4 days in a row during Weeks 1-2\n* 6-Thioguanine every day for the first 2 weeks.\n* Intrathecal methotrexate at Weeks 1 and 2\n* Vincristin at Weeks 3 and 4\n* PEG Asparaginase at Week 3\n\nOnce you finish Consolidation, you will then receive 24 months of Maintenance Therapy.\n\n* Vincristine every month.\n* Dexamethasone for 5 days every month.\n* 6-Mercaptopurine 1 time a day\n* Methotrexate by mouth every week.\n* If you have ALL, you will also receive intrathecal methotrexate every 3 months for the first 12 months of maintenance.\n\nStudy Tests/Procedures:\n\nInduction:\n\n* Blood (about 3 teaspoons) will be drawn about 2 times each week during the Induction Period for routine tests.\n* You will have a bone marrow aspirate or biopsy on Days 15 and 29 and then as needed to check the status of the disease.\n* About 7 days after you receive your first dose of PEG asparaginase, blood (about 1 tablespoon) will be drawn to check the activity of the drug in your blood. If the drug does not seem to be working well, your dose may be changed.\n* If you have LL and bone marrow was not found to be involved with the disease at screening, you will have a chest x-ray, CT scans, and positron emission tomography (PET) scans to measure the disease. These scans will be done after about 28 days of therapy.\n\nConsolidation 1:\n\n* Blood (about 3 teaspoons) will be drawn for routine tests about 2 times each week.\n* You will have a spinal tap during each intrathecal methotrexate dose. The spinal fluid will be checked for leukemia cells.\n* You will have a bone marrow aspiration at the end of Month 2 to check the status of the disease.\n\nConsolidation 2:\n\n* Blood (about 3 teaspoons) will be drawn every 2 weeks for routine tests.\n* You will have a spinal tap during each intrathecal methotrexate doses. The spinal fluid will be checked for leukemia cells.\n\nConsolidation 3 (Part A and B):\n\n* Blood (about 3 teaspoons) will be drawn at least weekly for routine tests.\n* You will have a spinal tap during each intrathecal methotrexate dose. The spinal fluid will be checked for leukemia cells.\n\nMaintenance:\n\n* You will have a spinal tap during each intrathecal methotrexate dose. The spinal fluid will be checked for leukemia cells.\n* You will have a bone marrow aspiration at least every 3-6 months to check the status of the disease.\n\nLength of Study:\n\nYou may remain on study for as long as the study doctor thinks it is in your best interest. If the disease does not appear to be improving after Induction, you will be taken off study. You may be taken off study if the disease gets worse or comes back during treatment, if intolerable side effects occur, if your doctor thinks it is in your best interest, or if you cannot follow the study instructions.\n\nFollow-up Visits:\n\nYour study doctor will inform you of your follow-up visit schedule in the clinic. At each follow-up visit there will be a physical exam and blood (about 1 tablespoon) will be drawn for routine tests. You will be followed-up for the next 3 years after your the last dose of your chemotherapy.\n\nThis is an investigational study. The chemotherapy drugs used in this study are all FDA approved and commercially available for the treatment of various types of leukemia. The use of ofatumumab/rituximab in this drug combination, as well as the drug combination's use in pediatric patients, is investigational.\n\nUp to 100 participants will be enrolled in this study. All will take part at MD Anderson."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT'], 'maximumAge': '30 Years', 'minimumAge': '12 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Patients must have precursor-B lymphoblastic leukemia or lymphoma.\n2. Patients must be untreated or have had only one prior chemotherapy regimen for ALL or LL . Previously treated patients will be analyzed separately.\n3. Age between 12 to 30 years old\n4. Patients with central nervous system (CNS) disease or testicular disease are eligible.\n5. Intrathecal therapy with cytarabine is allowed prior to registration for patient convenience. This is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture. Systemic chemotherapy must begin within 72 hours of the first intrathecal treatment.\n6. Signed informed consent prior to the start of systemic therapy. In the event of enrollment of a minor patient, an attempt to obtain assent from the patient must be documented, and parental consent must be signed.\n7. Echocardiogram should be done within 7 days of starting therapy if there are cardiac risk factors (e.g., history of hypertension or of myocardial infarction)\n8. Creatinine should be \\< 3 mg/dL bilirubin \\< 3 mg/dl unless due to disease\n9. Zubrod Performance status of \\<3\n10. Patients who received steroids more than 72 hours prior to study enrollment are eligible but will be analyzed separately.\n11. Lymphoblasts may have any positive expression of cluster of differentiation antigen 20 (CD20) for ofatumumab administration.\n\nExclusion Criteria:\n\n1. Age less than twelve years of age or greater than 30 years.\n2. More than one prior treatment regimen for ALL or LL.\n3. The patient is pregnant or unwilling to practice appropriate birth control.\n4. Presence of the Philadelphia chromosome t(9;22)\n5. Laboratory or clinical evidence of active infectious hepatitis.'}, 'identificationModule': {'nctId': 'NCT02419469', 'briefTitle': 'Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma', 'organization': {'class': 'OTHER', 'fullName': 'M.D. Anderson Cancer Center'}, 'officialTitle': 'Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma', 'orgStudyIdInfo': {'id': '2014-0396'}, 'secondaryIdInfos': [{'id': 'NCI-2015-00967', 'type': 'REGISTRY', 'domain': 'NCI CTRP'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Augmented BFM Therapy + Ofatumumab or Rituximab', 'description': 'Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.', 'interventionNames': ['Drug: Cytarabine', 'Drug: Daunorubicin', 'Drug: Vincristine', 'Drug: Prednisone', 'Drug: PEG asparaginase', 'Drug: Ofatumumab', 'Drug: Rituximab', 'Drug: Methotrexate', 'Drug: Cyclophosphamide', 'Drug: Mercaptopurine', 'Drug: Doxorubicin', 'Drug: Dexamethasone acetate', 'Drug: Thioguanine']}], 'interventions': [{'name': 'Cytarabine', 'type': 'DRUG', 'otherNames': ['Ara-C', 'Cytosar', 'DepoCyt', 'Cytosine Arabinosine Hydrochloride'], 'description': 'Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.\n\nConsolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.\n\nConsolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Daunorubicin', 'type': 'DRUG', 'otherNames': ['Daunorubicin Hydrochloride', 'Cerubidine', 'Daunomycin', 'DNR'], 'description': 'Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Vincristine', 'type': 'DRUG', 'description': 'Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.\n\nConsolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.\n\nConsolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.\n\nConsolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.\n\nConsolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.\n\nMaintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Prednisone', 'type': 'DRUG', 'description': 'Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'PEG asparaginase', 'type': 'DRUG', 'otherNames': ['Pegaspargase', 'Oncaspar', 'Polyethylene Glycol Conjugated Lasparaginase-H'], 'description': 'Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.\n\nConsolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.\n\nConsolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.\n\nConsolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.\n\nConsolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Ofatumumab', 'type': 'DRUG', 'otherNames': ['Arzerra'], 'description': 'Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.\n\nConsolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.\n\nConsolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.\n\nConsolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Rituximab', 'type': 'DRUG', 'otherNames': ['Rituxan'], 'description': 'Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.\n\nConsolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.\n\nConsolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.\n\nConsolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Methotrexate', 'type': 'DRUG', 'description': 'Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.\n\nConsolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.\n\nConsolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.\n\nConsolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.\n\nConsolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.\n\nMaintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.\n\nMaintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Cyclophosphamide', 'type': 'DRUG', 'otherNames': ['Cytoxan', 'Neosar'], 'description': 'Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.\n\nConsolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Mercaptopurine', 'type': 'DRUG', 'otherNames': ['6-Mercaptopurine', 'Purinethol', '6-MP'], 'description': 'Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.\n\nMaintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Doxorubicin', 'type': 'DRUG', 'otherNames': ['Doxorubicin Hydrochloride', 'Adriamycin PFS', 'Adriamycin RDF', 'Adriamycin', 'Rubex'], 'description': 'Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Dexamethasone acetate', 'type': 'DRUG', 'otherNames': ['Decadron'], 'description': 'Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.\n\nMaintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}, {'name': 'Thioguanine', 'type': 'DRUG', 'otherNames': ['6-thioguanine'], 'description': 'Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.', 'armGroupLabels': ['Augmented BFM Therapy + Ofatumumab or Rituximab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}], 'overallOfficials': [{'name': 'Michael E. Rytting, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'M.D. Anderson Cancer Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'M.D. Anderson Cancer Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Jazz Pharmaceuticals', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}